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Edited by Takashi GojoboriAbstract Adult liver functions are regulated by several hepa-
tocyte nuclear factors (HNFs). HNF4a and HNF1a are involved
in metabolic functions in the liver. The expression of proline
oxidase (PO) and proline dehydrogenase was downregulated in
the HNF4a liver-speciﬁc null mice. In addition, the expression of
PO was also diminished in the liver derived from HNF1a-null
mice. The )160 bp proximal promoter region of the PO gene has
two HNF4a- and HNF1a-binding consensus sites. Transactiva-
tion, electrophoretic mobility shift and chromatin immunopre-
cipitation studies revealed that these regions are important for
PO promoter activity. These results suggested that HNF4a and
HNF1a regulate proline metabolism in adult liver.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Adult liver is the central organ for intermediary metabolism,
serum protein synthesis, lipogenesis, detoxiﬁcation of xenobi-
otics, heme catabolism, amino acid catabolism and urea syn-
thesis. During organ development, cell diﬀerentiation takes
place which is a result of changes in gene expression that are
mainly regulated at the level of transcription. Previous studies
have suggested that hepatocyte nuclear factors (HNFs) 1a, 1b,
3a, 3b, 3c, 4a and 6 as well as the CCAAT/enhancer-binding
protein (C/EBP) family (a, b and d) are involved in both liver
development and the expression of mature liver functions.
HNF4a is a member of the nuclear hormone receptor su-
perfamily and several studies revealed that it is important for* Corresponding author. Fax: +1-301-496-8419.
E-mail address: fjgonz@helix.nih.gov (F.J. Gonzalez).
Abbreviations: HNF, hepatocyte nuclear factor; PO, proline oxidase;
C/EBP, CCAAT/enhancer-binding protein; PAH, phenylalanine hy-
droxylase; PDH, proline dehydrogenase; DMEM, Dulbecco’s Modi-
ﬁed Eagle’s Medium; FBS, Fetal bovine serum; RACE, rapid
ampliﬁcation of the cDNA ends methods; TO, tryptophan oxygenase;
FLOX, HNF4a-ﬂoxed-allele; OTC, ornithine transcarbamylase; CPS,
carbamoylphosphate synthetase-1; PPARa, peroxisome proliferator-
activated receptor a
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adult liver-speciﬁc disruption of HNF4a results in several de-
fects in liver functions such as the urea, lipid and bile acid
metabolism [2–4]. HNF1a, a homeodomain-containing tran-
scription factor preferentially expressed in the liver, regulates
many genes including CYP2E1, serum albumin, phospho-
enolpyruvate carboxykinase and phenylalanine hydroxylase
(PAH), all of which have a functional HNF1a-binding se-
quence in their upstream regulatory regions [5–8]. A role for
HNF1a in controlling mammalian development and metabo-
lism was suggested by analysis of HNF1a-null mice [9,10].
HNF1a-null mice are characterized by a phenotype resembling
non-insulin-dependent diabetes mellitus. In addition, the ex-
pression of PAH, the enzyme responsible for catabolism of
phenylalanine, was markedly diminished in HNF1a-null mice,
indicating that HNF1a regulates phenylalanine metabolism.
In addition to PAH, several enzymes regulating amino acid
metabolism are expressed in the adult liver. All tissues have
some capacity for synthesis of the non-essential amino acids,
amino acid remodeling and conversion of non-amino acid
carbon skeletons into amino acids and other derivatives that
contain nitrogen. However, the liver is the major site of amino
acid metabolism in the body. The amino acids including glu-
tamine, proline, arginine, and histidine are ultimately con-
verted to glutamate, which is deaminated to a-ketoglutarate.
The ﬁrst step of proline metabolism is the conversion of pro-
line to L-1-proline-5-carboxylate, followed by conversion to
ornithine, metabolism in the urea cycle or to glutamate and
ﬁnally introduction into the TCA cycle [11]. Proline oxidase
(proline dehydrogenase, PDH) is an important enzyme in the
ﬁrst step of proline metabolism and two mouse genes having
the PDH domain were cloned as kidney and liver proline ox-
idase 1 (PO) and brain and kidney proline oxidase 2 (PDH)
[12]. PDH has also been identiﬁed as p53-induced gene in a
colorectal cell line [13]. However, the molecular mechanism
regulating these two genes in adult liver remains unknown.
In this study, the liver speciﬁc transcriptional control of
proline metabolic enzymes by HNF1a and HNF4a was ana-
lyzed. Disruption of HNF4a caused the downregulation of
expression of PO and PDH. In addition, expression of PO was
also decreased in the liver derived from HNF1a-null mice. The
upstream regulatory region of the PO gene has both HNF4a
and HNF1a binding sites and these sites were required for
expression of PO induced by HNF4a and HNF1a. These data
indicate that HNF4a and HNF1a regulate proline metabolism
through expression of PO and PDH.ation of European Biochemical Societies.
Fig. 1. Expression of amino acid metabolic enzymes regulated by
HNF4a and HNF1a. (A) The neonatal, 2 and 6 month-old mice were
dissected. Total RNAs were puriﬁed from the liver and subjected to
Northern blot analysis. Expression of PDH and TO was barely
changed by the HNF1a gene inactivation. (B) Expression of PO and
PDH in the livers of control and HNF4a liver-null mice. The 45-days
livers derived from HNF4a FLOX and null mice were used for
Northern blot analysis. (C) Developmental changes of expression of
PO and PDH in the liver. Total RNAs isolated from E14, E16, neo-
natal, 5-, 9-, 14-, 21-, 42-day-old, and adult livers were used for
Northern blot analysis.
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2.1. Materials
Liver-speciﬁc HNF4a-null mice were generated by Cre-loxP medi-
ated deletion (in which the Cre gene is under the control of the albumin
promoter) [2]. HNF1a-null mice were produced as described previ-
ously [10]. Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) was pur-
chased from Gibco-BRL (Rockville, MD). Fetal bovine serum (FBS)
was purchased from HyClone (Logan, UT). Goat polyclonal anti-
human HNF4a antibody was from Santa Cruz Biotechnology (Santa
Cruz, CA). The expression vectors of HNF4a and HNF1a were pre-
viously described [3,14].
2.2. Northern blot analysis
Cellular and tissue total RNA samples were extracted with Trizol
reagent (Invitrogen, Carlsbad, CA). Ten lg of total RNA from each
sample was separated by electrophoresis on a 1.5% agarose gel con-
taining 2% formaldehyde. RNA was transferred to GeneScreen Plus
membranes (Dupont, Wilmington, DE) and the blots were hybridized
with 32P-labeled cDNA probes generated by random-prime labeling
reactions. The membrane and probe were incubated at 65 C in Per-
fectHyb Plus hybridization buﬀer (Sigma, St. Louis, MO) and fol-
lowing washing, the blot was exposed to a phosphorimager screen
cassette and the signals visualized using a Molecular Dynamic Storm
860 Phosphorimager system (Sunnyvale, CA). All probe cDNAs were
ampliﬁed from a mouse liver cDNA library by using gene-speciﬁc
primers and cloned into pCR TOPOII (Invitrogen). The identity of the
probes was conﬁrmed by nucleotide sequencing.
2.3. Determination of the transcription start site
The transcription start site of the mouse PO gene was determined
using 50 rapid ampliﬁcation of the cDNA ends methods (RACE) with
the GeneRacer Kit (Invitrogen). After ﬁrst-strand cDNA synthesis,
PCR was performed with a gene-speciﬁc antisense primer (50-AGA-
GCCCCCTTCCTGCCCACTCCATCCT-30) and 50 GeneRacer pri-
mer. To generate a gene-speciﬁc RACE PCR product, nested PCR was
performed with a gene-speciﬁc antisense nested primer (50-
TGCTCACCGCTAGTCCATGAGTGA-30) and 50 GeneRacer nested
primer. These primers were speciﬁc to the sequences in the PO exon 1.
The transcription start site was determined by sequencing the resultant
cloned PCR products. Since 19 out of 24 cDNAs had the exact se-
quence, this site was designated as the major transcription start site.
2.4. Construction of the mouse PO-luciferase promoter plasmids
The )775, )250, )160, )85 and )40/+24 bp fragments from the
transcription start site of the mouse PO promoter were ampliﬁed by
PCR and cloned into the luciferase reporter vector, pGL3basic (Pro-
mega, Madison, WI). Mutations were introduced into the HNF4a and
HNF1a binding sites in the PO gene promoter using PCR-based site-
directed mutagenesis. All plasmids were conﬁrmed by nucleotide se-
quencing.
2.5. Transient transfection luciferase assay
HepG2 cells and CV-1 cells were cultured in DMEM containing 10%
FBS, 100 units/ml penicillin/streptomycin (Invitrogen). The cells were
seeded in 24-well tissue culture plates, grown to 90–95% conﬂuency
and transfected with pGL3basic reporter plasmid and pSG5-
ratHNF4a or pCMV-ratHNF1a expression vectors using LipofectA-
MINE 2000 (Invitrogen). As an internal control, the plasmid pRL-TK
containing the Renilla luciferase gene was co-transfected. Cells were
cultured in medium for 48 h and then lysed with passive lysis buﬀer
(Promega). Luciferase activity was measured according to the technical
manual for the Dual-Luciferase Reporter Assay System (Promega).
2.6. Electrophoretic mobility shift assay
Nuclear extracts were prepared from wild-type and null mouse
livers using NE-PER nuclear and cytoplasmic extraction reagents
(Pierce, Rockford, IL). Three lg of protein extract was preincubated
at 4 C for 15 min in 10 mM Tris–HCl (pH 7.5), 60 mM KCl, 0.1%
NP-40, 6% glycerol, 1 lg poly(dI-dC) and 1 mM dithiothreitol. For
competition experiments, a 50-fold excess of unlabeled oligonucleo-
tide was added to the reaction mixture. 32P-end-labeled double
stranded oligonucleotide was then added and the reaction mixture
was incubated at 4 C for 20 min. For gel mobility super-shift as-
says, and antibodies against HNF4a and HNF1a (kindly providedby Dr. Jorge Ferrer, Hospital Clinic Universitari, Spain) were in-
cubated with the probe-nuclear extract mixtures for 30 min at 4 C.
DNA/protein complexes were resolved on a 5% polyacrylamide
(19:1, acrylamide:bisacrylamide) gel in 0.5· Tris–borate–EDTA at
150 V for 2 h at 4 C. The following oligonucleotides were used; the
PO promoter/HNF4a-B1, 50-TTCTGACCTCTGTCCCTAA-30 and
30-AAGACTGGAGACAGGGATT-50; HNF4a-B1 mutant oligonu-
cleotides, 50-TTCTGACCTCTGTCAGTAA-30 and 30-AAGACTG-
GAGACAGTCATT-30; HNF4a-B2, 50-AGCTGGGCAAGGGGC-
ATTT-30 and 30-TCGAC- CCGTTCCCCGTAAA-50; HNF4a-B2
mutant oligonucleotides, 50-AGCTTCGCAAGGGGCATTT-30 and
30-TCGAAGCGTTCCC- CGTAAA-50; HNF1a-B1, 50-CAT-
TAATTATTAACCCT-30 and 30-GTAATTAATAATTGGGA-50;
HNF1a-B1 mutant oligonucleotides, 50-CATCGGCTATTAACCCT-
30 and 30-GTAGCCGATAATTGGGA-50; HNF1a-B2, 50-AGTTA-
ATCAGTAACTGC-30 and 30-TCAATTAGTCATTGACG-50;
HNF1a-B2 mutant oligonucleotides, 50-AGTCGGCCAGTAACT-
GC-30 and 30-TCAGCCGGTCATTGACG-30 (mutations are un-
derlined).
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A total of 0.1 mg adult liver tissues derived from HNF4a FLOX and
null mice were used for assays. Chromatin immunoprecipitation ex-
periments were performed according to the technical manual for the
Chromatin Immunoprecipitation Assay Kit (Upstate, Lake Placid,
NY). Sonication was performed 8 times on ice for 10 s at 20-s intervals.
A volume of sonicated DNA was then immunoprecipitated by using
the anti-human HNF4a mouse monoclonal antibody (Clone No.
K9218, Perseus Proteomics Inc.) [15]. All immunoprecipitations were
subjected to a round of preclearing with an excess of protein A-Aga-
rose to ensure the speciﬁcity of the reaction. Precipitated and non-
precipitated (input) genomic DNA was then puriﬁed and resuspended
and one tenth of the DNA preparations were PCR-ampliﬁed for 45
cycles (30 s at 95 C, 30 s at 50 C, and 30 s at 72 C). The following
primers were used; PO )250/+24, 50 primer: 50-TGCTTATTCAG-
CAATGCAAGCTG-30 and 30 primer: 50-CAAGTGCCTG-
GTTACCACCACACTAG-30; PO +1034/+1249, 50 primer:
50-TCAGTTGCTGAGCATGGTCGTG-30 and 30 primer: 50-GGA-
GAGACGGCTGCATTTTCTG-30.3. Results
3.1. Expression of proline oxidase enzymes regulated by HNF1a
and HNF4a
Proline oxidation (dehydrogenation) is the ﬁrst step of
proline metabolism. Two mouse genes, PO and PDH, have a
proline dehydrogenase consensus domain. However, there is
little information on the mechanism of regulation of these
genes. Recently, mouse oligonucleotide microarrays using
HNF1a-null mice revealed that several known genes and EST
clones displayed a greater than 50% decrease in expression in
HNF1a-null mouse liver [16]. One of these genes was PO and
consistent with the microarray result, the expression of this
gene was signiﬁcantly downregulated in HNF1a-null liver as
assessed by Northern blots (Fig. 1A). In contrast, the expres-
sion of other amino acid metabolic enzymes, PDH and tryp-
tophan oxygenase (TO), was not changed in adult liver derived
from HNF1a-null mice. The expression of genes involved in
proline metabolism was analyzed in HNF4a-null livers
(Fig. 1B). Expression of both PO and PDH was signiﬁcantlyFig. 2. Nucleotide sequence of the )250 bp fragment of the PO
proximal promoter. Numbering of nucleotides is relative to the tran-
scription start site (nucleotide +1, arrow). The asterisk marks the
translation start site. The two putative HNF4a binding sites (HNF4a-
B1 and HNF4a-B2) and two putative HNF1a binding sites (HNF1a-
B1 and HNF1a-B2) are found in the proximal promoter region of the
PO gene.decreased by liver-speciﬁc deletion of the HNF4a gene,
whereas expression of TO was not downregulated by targeted
inactivation of HNF4a in the liver. These results suggest that
expression of genes encoding proline oxidase enzymes was
regulated by HNF4a and HNF1a either directly or indirectly.
During liver development, the expression of PDH was not
detected in the fetal and perinatal livers, whereas PO was ex-
pressed during both the fetal and adult stages (Fig. 1C).
3.2. The PO proximal promoter region has HNF4a and HNF1a
putative binding consensus sequences
The inactivation of HNF4a resulted in a 50% less lower
HNF1a expression (Fig. 1B). In contrast, the expression of
HNF4a was not changed in HNF1a-null livers (Fig. 1A). ToFig. 3. Promoter analyses of the mouse PO gene. (A) Various luciferase
reporter plasmids containing mouse PO promoter ()775, )250, )160,
)85 and )40/+24 bp from the transcription start site) were transfected
into HepG2 cells. (B) CV-1 cells were cotransfected with the HNF4a or
HNF1a expression vector as indicated. The relative activity to
pGL3basic of the most active promoter (pGL3PO/)775+HNF4a)
was 19.2. (C) HepG2 cells were cotransfected with the HNF4a ex-
pression vector as indicated. ‘‘Mock’’ shows that the cells transfected
with PUC19 instead of the expression vectors. The relative activity to
pGL3basic of the most active promoter (pGL3PO/)250+HNF4a)
was 170. The fold induction was calculated. Each point is the mean
and SD of triplicate assays.
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HNF4a-null livers is due to HNF1a, a DNA fragment con-
taining the 50 ﬂanking region of the mouse PO gene was iso-
lated and the precise transcription start site was determined by
50 RACE using the sense and antisense nested primers speciﬁc
to the sequences within the coding region of the PO gene. After
sequencing the PCR products, the major transcription start
site was determined to be )26 bp upstream of the translation
start site (Fig. 2). Interestingly, the )160 bp upstream fragment
of the PO gene has two putative tandem HNF4a and HNF1a
binding sites.
Several PO promoter-luciferase reporter plasmids were
constructed and analyzed by transient transfections. When
HepG2 cells were used for transient transfections, the pro-
moter activities of the )160 bp and longer fragments were
signiﬁcantly higher than that obtained with the )85 and )40
bp fragments (Fig. 3A). This indicated that the elements im-
portant for hepatic transcription are within 160 bp of the PO
gene transcription start site that has HNF4a and HNF1a
binding sequences. Next, to determine the eﬀects of HNF4a
and HNF1a on the PO promoter, non-hepatic CV-1 cells were
used. Basal activities of the )85 and )40 bp fragments were
lower than the activities of the )250 and )775 bp fragments
(data not shown). However, the activity of the )85 bp frag-
ment, in addition to the )250 and )775 bp fragments, was also
increased by co-expression of HNF4a and HNF1a (Fig. 3B).
This result is consistent with the )85 bp upstream region of the
PO promoter having HNF4a and HNF1a binding sites
(Fig. 2). In contrast, the )40 bp upstream fragment, which has
no HNF4a or HNF1a binding site, was not activated by co-
expression of HNF4a and HNF1a. Similarly to CV-1 cells,
HNF4a induced the activity of the )85 bp upstream region of
the PO promoter but not the )40 bp upstream fragment inFig. 4. Electrophoretic mobility shift assays for HNF4a and HNF1 bindin
HNF4a FLOX or null livers were incubated with labeled wild-type (B1WT
oligonucleotides. For super-shift assays, 1 lg of an HNF4a antibody was add
excess of unlabeled oligonucleotides was added to the reaction mixture. (B)
were incubated with labeled wild-type (B1WT and B2WT) and mutant (B1mu
shows the eﬀect of HNF1a and HNF4a antibodies on the HNF1a-B1WT aHepG2 cells (Fig. 3C). In contrast, the overexpression of
HNF1a induced the activity of pGL3basic almost ten times in
HepG2 cells. It is possible that some associating protein in
HepG2 cells aﬀects the vector sequence of pGL3basic in co-
operation with HNF1a (data not shown).
3.3. Identiﬁcation of HNF4a and HNF1a binding sites in the
PO proximal promoter
The )160 bp fragment derived from the PO promoter was
found to have two putative HNF4a and HNF1a binding sites.
To prove that these sites directly bind to HNF4a, electro-
phoretic mobility shift assays (EMSAs) were performed using
crude liver nuclear extracts from HNF4a liver null and control
(HNF4a-ﬂoxed allele, FLOX) mice (Fig. 4A). Liver nuclear
extracts from HNF4a FLOX mice contained proteins that
bound to both HNF4a binding site oligonucleotides (WT)
(Fig. 4A, lanes 1 and 8). In addition, super-shifted fragments
were detected using the HNF4a-speciﬁc antibody (Fig. 4A,
lanes 3 and 10). In contrast, the super-shifted fragments were
not found in samples derived from HNF4a null liver nuclear
extracts (Fig. 4A, lanes 5 and 12). To conﬁrm the speciﬁcity of
HNF4a binding to these sites, mutations were introduced to
change 2 nucleotides (CC to AG of HNF4a-B1 and GG to TC
of HNF4a-B2). The mutated oligonucleotides were unable to
bind to HNF4a (Fig. 4A, lanes 7 and 14).
In addition, the binding activities of HNF1a binding con-
sensus sequences were studied. Shifted bands were detected
using liver nuclear extracts from wild-type mice (Fig. 4B,
lanes 1 and 7), but not from HNF1a-null mice (lanes 3 and
9). To conﬁrm the speciﬁcity of HNF1a binding to these
sites, mutated oligonucleotides were synthesized within 4
nucleotides changes (TAAT to CGGC) of the HNF1a
binding sites. HNF1a did not bind to these mutated oligo-g sites in the PO promoter. (A) Nuclear extract proteins (3 lg) from
and B2WT) and mutant (B1mut and B2mut) PO HNF4a binding site
ed to probe-extract complexes. For competition experiments, a 50-fold
Nuclear extract proteins from HNF1a wild-type (WT) and null livers
t and B2mut) PO HNF1a binding site oligonucleotides. The right panel
nd HNF1aB2WT oligonucleotide-bound complexes.
Fig. 5. Analysis of HNF4a and HNF1a binding sites in the PO pro-
moter by transactivation assay. (A) Reporter plasmids and an ex-
pression vector (HNF4a or HNF1a) were co-transfected into CV-1
cells. The induction of PO promoter plasmids containing mutation in
both HNF4a binding sites ()250 HNF4a-m1m2) was signiﬁcantly
decreased by the overexpression of HNF4a. The relative activity to
pGL3basic of the most active promoter (pGL3PO/)250+HNF4a)
was 26.1. (B) Analysis of constructs containing mutations of both
HNF1a binding sites in the PO promoter. The relative activity to
pGL3basic of the most active promoter (pGL3PO/)250+HNF4a)
was 23.0. The fold induction was calculated. ‘‘Mock’’ shows that the
cells transfected with PUC19 instead of the expression vectors. Each
point is the mean and SD of triplicate assays.
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HNF1a produced super-shifted the complexes with both
HNF1a-B1WT and HNF1a-B2WT (Fig. 4B, right panel). No
super-shifted fragments were detected with either oligonu-
cleotide with antibody against HNF4a. These results suggest
that the HNF4a and HNF1a putative binding sites in the PO
proximal promoter are capable of binding to HNF4a and
HNF1a.
3.4. HNF4a and HNF1a activate the PO promoter through the
HNF4a and HNF1a binding sites in the )160 bp upstream
region
To determine the functional relevance of these HNF4a and
HNF1a binding sites, CV-1 cells were transiently transfected
with the PO promoter plasmid containing mutated binding
sites shown in Fig. 4. The basal activities of )250 bp fragment
of PO were not signiﬁcantly changed by introducing mutations
in the HNF4a binding sites (data not shown). In the cells
transfected with the wild-type and HNF4a-binding site mutant
promoter plasmids, the fold induction of the luciferase activi-
ties by the overexpression of HNF1a was similarly detected
(Fig. 5A, black bars). In contrast, mutation of each HNF4a
binding site caused signiﬁcant decrease of the induction by the
co-expression of HNFa and the minimum induction was de-
tected using the promoter having both mutated HNF4a
binding sites (Fig. 5A, gray bars). In addition, mutations were
introduced into the HNF1a-binding sites in the PO promoter.
Mutation of HNF1a binding sites decreased basal luciferase
activities of the PO promoter (data not shown). When both
HNF1a binding sites were mutated, the PO promoter activity
was not signiﬁcantly induced when co-transfected with the
HNF1a expression plasmid (Fig. 5B, black bars), but not
HNF4a (Fig. 5B, gray bars). These results suggested that the
HNF4a and HNF1a binding sites were important for the ac-
tivity of the PO promoter.
3.5. HNF4a occupies the HNF4a binding sites in the )160 bp
upstream fragment of the PO gene in vivo
Occupancy of the PO promoter by HNF4a in intact he-
patocytes was studied by using chromatin immunoprecipita-
tion assays performed on DNA from HNF4a FLOX and null
adult livers. Chromatin DNA was precipitated using anti-
HNF4a antibody and the sequence covering the HNF4a
binding sites was ampliﬁed using speciﬁc primers. As a nega-
tive control, when the same DNA samples were ampliﬁed with
primers covering a distal region of the PO gene, no signal was
observed (Fig. 6, middle panel). The PO )250/+24 fragment
was signiﬁcantly ampliﬁed when samples were precipitated
using anti-HNF4a antibody but not without antibodies
(Fig. 6, lower panel). These results suggested the binding of
HNF4a to this DNA region in the in vivo adult liver.Fig. 6. HNF4a binds to the HNF4a binding sites in the PO promoter
in the in vivo liver. Soluble chromatin was prepared from the HNF4a
FLOX and KO adult livers, and immunoprecipitated with the anti-
HNF4a antibody. Samples immunoprecipitated and incubated with
protein A-Agarose (IP/HNF4a) or extracted DNA (Input) were am-
pliﬁed using pair of primers covering the HNF4a binding sites (PO
)250/+24) or a distal region of the PO gene (PO +1034/+1249) as a
negative control. The samples derived from HNF4a FLOX mice were
also precipitated with the anti-HNF4a antibody (+a) or without an-
tibodies ()a). Then, DNA was ampliﬁed.4. Discussion
This study revealed that the expression of PO and PDH was
regulated by HNF1a and HNF4a. In the HNF4a liver-speciﬁc
null mice, expression of PO and PDH was signiﬁcantly de-
creased. In addition, deletion of the HNF1a gene suppressed
expression of PO but not PDH, suggesting that both factors
were involved in the control of this gene. Indeed, two HNF4a
and HNF1a binding sites were found in the proximal pro-
68 A. Kamiya et al. / FEBS Letters 578 (2004) 63–68moter region of the PO gene. HNF4a and HNF1a were
found to directly bind to these regions and thus indicating that
these binding sites were important for the activity of the PO
promoter.
Human and mouse PDH was previously cloned as homolog
of sluggish-A, a Drosophila melanogaster gene responsible for
the behavioral phenotype of the slgA mutant [17,18]. Here, it
was shown that expression of PDH was downregulated by
HNF4a inactivation. However, the proximal PDH promoter
was not activated by co-expression of HNF4a (data not
shown). Expression of PDH was induced by p53 in tumor cell
lines [13,19], yet, the molecular mechanism of regulation of
PDH expression in intact animals remains unknown. The
current study indicated that PO is expressed in both neonatal
and adult stage livers. However, PDH mRNA was mainly
expressed in the adult liver. It was previously found that
plasma and brain proline levels were upregulated in mice
containing a mutation in the PDH gene, suggesting that this
gene is important for proline metabolism [18]. In contrast to
adult mice, expression of PDH was not detected in the fetal
and neonatal liver, suggesting that PO might be important for
the ﬁrst step of proline conversion in the fetal and neonatal
stages. Expression of PO mRNA was regulated by HNF4a and
HNF1a in the liver. It is noteworthy that HNF1a is directly
regulated by HNF4a in the developing liver [20] and both
HNFs are important for liver development. Previous results
indicated that the expression of HNF4a was induced by he-
patic maturation factor in fetal hepatic primary culture [21].
Thus, it is possible that these liver-enriched transcription fac-
tors regulate proline metabolism through the regulation of PO
gene expression during embryonic and postnatal development.
In the HNF4a liver-speciﬁc null mice, the expression of two
proline oxidase genes was signiﬁcantly decreased in the liver.
Proline is ultimately metabolized in the converged pathways of
glutamate or arginine catabolism. The main arginine metabolic
pathway is the urea cycle. Ammonia, derived from deamina-
tion reaction of a-amino groups of amino acids, is toxic to
animals and thus the urea cycle is an essential pathway for
elimination of ammonia through its conversion to urea. Since
the enzymes involved in this pathway are highly expressed in
the liver, this organ has an essential role in the urea cycle.
Previous studies revealed that ornithine transcarbamylase
(OTC), the second enzyme in the urea cycle, is directly regu-
lated by HNF4a. In contrast, HNF4a may negatively regulate
the expression of carbamoylphosphate synthetase-1 (CPS) and
arginase [3]. The activation of peroxisome proliferator-acti-
vated receptor a (PPARa) repressed the expression of CPS andarginase [22]. Expression of PPARa was downregulated in the
HNF4a null livers [2], indicating that this decrease caused the
upregulation of these genes in the HNF4a liver-null mice.
These results suggested that HNF4a is the key transcription
factor in the amino acid and urea metabolic pathways.
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